Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE: ibandronate versus zoledronate for nephrotoxicity in multiple myeloma
2005-003264-38Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ibandronic acid and zoledronic acid in multiple myeloma (MM) (2 arms), sponsored by Roche. Primary endpoints: Renal safety based on serum creatinine increase and Renal function deterioration ratio. Started Oct 2005; status: completed.
02
Drugs
ibandronic acidzoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-003264-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003264-38.